Company Overview and News
2018-10-11 seekingalpha - 5
FSIC was my smallest position and I sold before the recent declines for the reasons discussed in this article.
CCT AIY AINV CLA SDRPQ MCQ HRZN HTF KAP BKCC MCV BBDC OSLE MM ACTPF KCAP ABDC HTFA TSG CPTA FDMCF AST MCC GSBD HDSN TCRX GARS HCAPL MMCC FSIC TCPC AIB TCRD TCRZ PSEC SD TSLF OCSI SDOCQ OCSL MCX HCAP SDRXP PBB SDRXQ
TCPC is a higher quality BDC and is currently trading lower (below book value) for the reasons discussed in this article.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA
October's U.S. Exchange monthly-paid dividends; upsides; net gains: 1. Stocks by yield >0.5% (87); 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds and Notes (CEICs/ETFs/ETNs) by yield (80).
SCA CLA GOOD GECC HRZN HTF ORC OXLCO ROYT OXLCN MORL SCM GOODM ATGFF GOODN THO ECC LMLP HTFA ECCZ DVHL AGNC CPTA ECCY GOODO GOODP TAHO CEFL HCAPL OXLC ECCB SCQ ECCA HCAP SUNS PVL GNL ALA
2018-08-30 seekingalpha - 1
September's forecast for U.S. monthly-paid dividends, upsides, and net-gains: 1. Stocks by yield >0.5% (69); 2. Stocks by price-upside (30); 3. Closed-End Investments, Exchange-Traded Funds and Notes (CEICs/ETFs/ETNs) by yield (80).
SCA CLA GOOD HRZN HTF ORC OXLCO VET ROYT OXLCN SCM GLADO GOODM GLAD GOODN THO HTFA AGNC CPTA AHOTF DR.DB.A GOODO GOODP JMP TAHO DR HCAPL APLE JMPB JMPC JMPD MFCSF OXLC ARR SCQ HCAP SUNS GNL VET
Most BDCs with higher exposure to oil-related investments have rebounded over the last two quarters partially due to rising oil prices and LIBOR resulting in higher book values and earnings.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD NMFC TSLF MCX HCAP CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA
PNNT has rallied 15% since my previous article predicting that the company would report increased book value/NAV per share due to rebounding oil prices and accretive share repurchases.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN PNNT MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA
Fidus has outperformed most BDCs when it comes to NAV per share growth, but declined during the recent quarter with realized losses mostly due to the exits of two investments.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC
I have been making purchases of 'higher quality' BDCs this year including GBDC due to consistent dividend coverage, NAV per share growth, and special dividends, delivering higher returns to shareholders.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX GSBD HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC
Greetings, and welcome to the Catasys Incorporated 2018 Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
HBS CATS HTFA HTF HRZN
The August forecast for U.S. Exchange monthly-paid dividends, upsides, and net-gains: 1. Stocks-by-yield >0.25% (94); 2. Stocks-by-price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by-yield 80.
SCA CLA HCFT GOOD GECC HRZN HTF ORC ROYT SCM HIE GOODM GOODN THO CJR.B HTFA AGNC CPTA GOODO GOODP TAHO GXOCF HCAPL PSEC CJREF SCQ GXO HCAP SUNS PBB
Good morning and welcome to Horizon Technology Finance’s Second Quarter 2018 Conference Call. Today’s call is being recorded. All lines have been placed on mute. We will conduct a question and answer session after the opening remarks. Instructions will follow at that time.
CLSN HTFA HRZN HTF
Access National Corporation (ANCX - Free Report) is the bank holding company for Access National Bank. The Zacks Consensus Estimate for its current year earnings has been revised 3.9% downward over the last 30 days.
CZZ ANCX DEI ASHTY ASHTF HTFA HTF HRZN AHT ALGT
Horizon Technology Finance (HRZN - Free Report) just came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.
APC HTFA HRZN HTF ROG UTX AEUA ULTI
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET